ValueLabs Wins Nine Globee® Awards, Validates Position as Agentic AI Services Leader

HYDERABAD, India, May 26, 2025 /CNW/ -- ValueLabs has been recognized at the 2025 Globee® Awards for Artificial Intelligence, winning eight Gold and one Bronze awards across key categories. This recognition reinforces the company's position as an Agentic AI Services company and their standing as a true Category of One.
When Generative AI burst onto the scene 28 months ago, ValueLabs saw it as both an existential threat and a once-in-a-generation opportunity for reinvention. Their response was immediate and decisive.
They declared their traditional business model obsolete and built AiDE®, their Enterprise Operating System, which now powers every function of the organization. With full internal adoption, they are able to deliver solutions at unprecedented speed and scale.
AiDE® acts like an 'Ironman suit' for their designers, architects, developers, and testers — amplifying productivity, improving quality, and making the art of the possible come alive. This democratization of expertise has fundamentally transformed how their teams operate across the entire software development lifecycle.
Beyond traditional AI use cases, their Vertical AI consulting and solutions enable enterprises to reimagine their entire business models for an AI-first world. By combining deep domain expertise with Agentic AI capabilities, they help organizations transform industry-specific processes into intelligent, autonomous workflows that drive measurable business outcomes.
This recognition by the Globee® Awards across a wide spectrum of categories underlines the platform's versatility and real-world impact across industries. ValueLabs was awarded in the following categories:
Gold Awards:
Artificial Intelligence Company of the Year: ValueLabs
Best Achievement in Artificial Intelligence Operations: AiDE Operations
Best AI Platform: AiDE®
Best AI-driven Personalization Solution: AiDE UX
Best AI-driven Automated Testing Solution: AiDE QE
Best AI-powered Customer Insights Solution: AiDE Conversational Insights
AI-Driven Threat Detection: AiDE Shield
Most Innovative Artificial Intelligence Tool for Customer Service: AiDE Chat
Bronze Award:
Best AI-based Knowledge Management Solution: AiDE Academy
"These awards reflect the natural evolution of our 28-year journey," said Arjun Rao, Founder and Chairman, ValueLabs. "We are not just implementing AI. We are reimagining entire value chains and building autonomous capability across every function. Our move into Agentic AI Services is not a reaction to the moment — it is a continuation of everything we have been building toward."
Sam Alva, CEO, ValueLabs, noted, "We're practicing what we preach. AiDE® transforms every aspect of our business — from how our consulting teams shape strategy to how our delivery teams bring strategy to life. It powers how we build proposals, onboard clients, and drive outcomes at scale. Our Vertical AI solutions are opening new possibilities for clients to reimagine their industry-specific challenges with intelligence and speed. The recognition from the Globee® Awards, along with recent honors from Stevie and World HRD awards, affirms that we have moved from the art of the possible to the science of the real."
The company's approach reflects what many now refer to as 'Service-as-Software' — transforming work once done traditionally, manually into intelligent systems that deliver outcomes at scale. This model allows enterprises to rethink how to operate in an AI-first world.
With more than 7,000 employees worldwide, ValueLabs helps organizations move beyond tool adoption to become truly AI-native businesses. While research shows that 87 percent of enterprises are still in the pilot phase with AI, ValueLabs has reached full production scale across its own operations. The nine Globee® Awards underscore the company's unique position at the intersection of traditional consulting, cutting-edge technology, and Agentic AI delivery across both horizontal platforms and vertical industry solutions.
About ValueLabs
Founded in 1997, ValueLabs is a global Agentic AI Services company helping enterprises transition into AI-native businesses. At the core of this transformation is AiDE® — our proprietary platform for AI Driven Everything. This enterprise-grade platform functions as an OS for intelligent work across engineering, operations, and business functions.
With AiDE®, we've created a category of our own: combining platform innovation, consulting depth, and outcome-based delivery to solve enterprise-scale challenges. From strategy to execution, we design and deploy tailored AI solutions through both horizontal capabilities and vertical industry offerings.
With a Client NPS of 90 and an Employee NPS of 80, our relationships are built on trust, measurable impact, and long-term value creation.
Logo: https://mma.prnewswire.com/media/1343811/ValueLabs_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/valuelabs-wins-nine-globee-awards-validates-position-as-agentic-ai-services-leader-302465196.html
SOURCE ValueLabs LLP
View original content: http://www.newswire.ca/en/releases/archive/May2025/26/c0745.html

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

19 hours ago

• Yahoo

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference

HERZLIYA, Israel and CALGARY, AB, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan. "This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation:Iris Bincovich, CEO+1 5162104025+972-54-3012842+442037699377info@ NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo: View original content: SOURCE Innocan Pharma Corporation View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Business Wire

21 hours ago

• Business Wire

Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Bausch + Lomb Corporation ('BLCO' or the 'Company') (NYSE: BLCO) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On March 27, 2025, BLCO disclosed that it had '[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)' and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses. On this news, BLCO's stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors. Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that 'as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.' On this news, BLCO's stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding BLCO should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

USA Today

21 hours ago

• USA Today

Marquis Who's Who Listee Brian Fricker Featured on Innovator's Journey to Discuss Staffing Partners Inc.

Brian Fricker, president of Staffing Partners Inc., was featured on Innovator's Journey to discuss the unique staffing services his company offers. Under Mr. Fricker's leadership, Staffing Partners Inc. has become one of the top staffing agencies in the state of Wisconsin. Unlike other staffing companies, the agency offers transportation and PPE equipment for all employees. Through the BakPak division, the company is able to provide a warehouse space with a forklift and loading dock where clients can have assembly, packaging and fulfillment services completed. Looking to the future, Mr. Fricker hopes to expand Staffing Partners Inc. out of Wisconsin. For more information, visit About Marquis Who's Who®: Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at For more information about TV Interviews, please contact us at tvinterviews@